| Nodo | Tipo | Descripción | Visible | Grupos | Conexiones | Relevancia | Intermediación | Cercanía | Nuclearidad |
|---|---|---|---|---|---|---|---|---|---|
| Acido clodrònico | Visibilidad | 2.00 | 1.00 | 0.05 | 0.00 | 0.13 | 1.00 | ||
| Alendronato | Visibilidad | 1.00 | 16.00 | 0.56 | 9.88 | 0.14 | 9.00 | ||
| Alendronato + Placebo | Visibilidad | 4.00 | 3.00 | 0.00 | 1.00 | 0.07 | 2.00 | ||
| Denosumab | Visibilidad | 2.00 | 5.00 | 0.23 | 0.10 | 0.13 | 4.00 | ||
| Etidronato | Visibilidad | ||||||||
| Placebo | Visibilidad | 2.00 | 23.00 | 0.94 | 17.56 | 0.14 | 14.00 | ||
| PTH + TRH | Visibilidad | 5.00 | 1.00 | 0.00 | 0.00 | 0.07 | 1.00 | ||
| Raloxifeno | Visibilidad | 1.00 | 2.00 | 0.06 | 0.00 | 0.13 | 2.00 | ||
| Ranelato de estroncio | Visibilidad | 2.00 | 2.00 | 0.10 | 0.00 | 0.13 | 2.00 | ||
| Risedronato | Visibilidad | 1.00 | 7.00 | 0.29 | 0.00 | 0.13 | 7.00 | ||
| Teriparatide | Visibilidad | 2.00 | 30.00 | 1.00 | 21.28 | 0.14 | 14.00 | ||
| Teriparatide + Alendronato | Visibilidad | 3.00 | 4.00 | 0.15 | 0.18 | 0.13 | 3.00 | ||
| Teriparatide + Denosumab | Visibilidad | 2.00 | 3.00 | 0.12 | 0.00 | 0.13 | 3.00 | ||
| Teriparatide + Placebo | Visibilidad | 4.00 | 2.00 | 0.00 | 0.00 | 0.07 | 2.00 | ||
| Teriparatide + Raloxifeno | Visibilidad | 3.00 | 3.00 | 0.12 | 0.00 | 0.13 | 3.00 | ||
| Teriparatide + TRH | Visibilidad | 5.00 | 1.00 | 0.00 | 0.00 | 0.07 | 1.00 | ||
| TRH | Visibilidad | 5.00 | 2.00 | 0.00 | 1.00 | 0.07 | 1.00 |
| Origen | Relación | Destino | Fecha |
|---|---|---|---|
| Acido clodrònico | Tanakol | Placebo | |
| Alendronato | Tanakol | Placebo | |
| Alendronato | Idollazi | Placebo | |
| Alendronato | Tucci | Placebo | |
| Alendronato | Rizzoli | Placebo | |
| Alendronato | Takada | Risedronato | |
| Alendronato | Sebba | Risedronato | |
| Alendronato | Reid | Risedronato | |
| Alendronato | Reid | Risedronato | |
| Alendronato | Finkelstein | Teriparatide + Alendronato | |
| Denosumab | Sugimoto | Placebo | |
| Denosumab | Idollazi | Teriparatide + Denosumab | |
| PTH + TRH | Lane | TRH | |
| Raloxifeno | Sanad | Alendronato | |
| Raloxifeno | Sanad | Alendronato | |
| Ranelato de estroncio | Reginster | Placebo | |
| Ranelato de estroncio | Roux | Placebo | |
| Risedronato | Reginster | Placebo | |
| Teriparatide | Panico | Alendronato | |
| Teriparatide | Body J-J | Alendronato | |
| Teriparatide | Finkelstein | Alendronato | |
| Teriparatide | Keaveny | Alendronato | |
| Teriparatide | Gallagher | Alendronato | |
| Teriparatide | Tsai | Denosumab | |
| Teriparatide | Leder | Denosumab | |
| Teriparatide | Leder | Denosumab | |
| Teriparatide | Harvey | Placebo | |
| Teriparatide | Miyuachi | Placebo | |
| Teriparatide | Delmas | Placebo | |
| Teriparatide | Gallagher | Placebo | |
| Teriparatide | Schnell | Placebo | |
| Teriparatide | Krege | Placebo | |
| Teriparatide | Fujita | Placebo | |
| Teriparatide | Miyuachi | Placebo | |
| Teriparatide | Ito | Placebo | |
| Teriparatide | Marcus | Placebo | |
| Teriparatide | Neer | Placebo | |
| Teriparatide | Gallagher | Placebo | |
| Teriparatide | Chen P | Placebo | |
| Teriparatide | Harvey | Placebo | |
| Teriparatide | Hadji | Risedronato | |
| Teriparatide | Anastasilakis | Risedronato | |
| Teriparatide | Finkelstein | Teriparatide + Alendronato | |
| Teriparatide | Leder | Teriparatide + Denosumab | |
| Teriparatide | Idollazi | Teriparatide + Denosumab | |
| Teriparatide | Deal | Teriparatide + Raloxifeno | |
| Teriparatide + Alendronato | Muschitz | Teriparatide | |
| Teriparatide + Alendronato | Muschitz | Teriparatide + Raloxifeno | |
| Teriparatide + Placebo | McClung | Alendronato + Placebo | |
| Teriparatide + Placebo | Langdahl | Alendronato + Placebo | |
| Teriparatide + Raloxifeno | Muschitz | Teriparatide | |
| Teriparatide + TRH | Lindsay | TRH |
Visualizaciones e historias relacionadas
